Regeneron has demonstrated strong performance across crucial financial metrics, and we contend this is not fully captured in its current stock valuation, which renders it an attractive investment.

REGN stock has seen an impact that was slightly ... as evident in HQ Portfolio performance metrics. The views and opinions expressed herein are the views and opinions of the author and do not ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Tech Stock News IPO News Artificial Intelligence (AI) ... REGN Regeneron Pharmaceuticals, Inc. ... Performance Risk EPS Revisions Income Statement (TTM) ...

Citigroup has reduced Regeneron Pharmaceuticals’ price target from $700 to $650, though it still maintains a “buy” rating.

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Get the latest news on Regeneron Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Regeneron Pharmaceuticals performance ...

Regeneron Pharmaceuticals REGN +2.20% Get Free Report has outperformed the market over the past 15 years by 9.69% on an ...

We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi SNY reported results from two late-stage studies, AERIFY-1 and AERIFY-2 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...